GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncolytics Biotech Inc (NAS:ONCY) » Definitions » 3-Year EPS without NRI Growth Rate

Oncolytics Biotech (Oncolytics Biotech) 3-Year EPS without NRI Growth Rate : 10.40% (As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Oncolytics Biotech 3-Year EPS without NRI Growth Rate?

Oncolytics Biotech's EPS without NRI for the three months ended in Dec. 2023 was $-0.06.

During the past 3 years, the average EPS without NRI Growth Rate was 10.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 17.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Oncolytics Biotech was 37.00% per year. The lowest was -13.30% per year. And the median was 17.50% per year.


Competitive Comparison of Oncolytics Biotech's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Oncolytics Biotech's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncolytics Biotech's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncolytics Biotech's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Oncolytics Biotech's 3-Year EPS without NRI Growth Rate falls into.



Oncolytics Biotech 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Oncolytics Biotech  (NAS:ONCY) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Oncolytics Biotech 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Oncolytics Biotech's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncolytics Biotech (Oncolytics Biotech) Business Description

Industry
Traded in Other Exchanges
Address
322 11th Avenue S.W, Suite 804, Calgary, AB, CAN, T2R 0C5
Oncolytics Biotech Inc is a development-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. Its clinical development plan has the approval of its products as quickly as possible and expands its products into commercially valuable new treatment areas as objectives. The primary focus is to advance programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies.